[A23-53] Sotorasib (NSCLC) – Addendum to Commission A23-06

Last updated 03.08.2023

Project no.:
A23-53

Commission:
Commission awarded on 06.06.2023 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adults with advanced non-small cell lung cancer with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy

Result of dossier assessment:

Unchanged after addendum

  • After first-line therapy with cytotoxic chemotherapy: added benefit not proven
  • After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing chemotherapy: added benefit not proven
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2023-08-03 A G-BA decision was published.
G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form